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Introduction
============

VEGF plays an important role in the formation of new vessels during embryogenesis and in proliferative diseases in the adult ([@bib20]; [@bib8]; [@bib17]). This effect is mediated by the capacity of the growth factor to induce endothelial cell proliferation and differentiation in vascular structures.

VEGF acts by binding to two high affinity receptor tyrosine kinases: VEGF receptor (VEGFR)[\*](#fn1){ref-type="fn"} 1 also called Flt-1, and VEGFR-2, also called Flk-1/KDR. Although the role of VEGFR-1 in VEGF signaling is still debated, VEGFR-2 is effective in transducing signals regulating cell division and inhibition of cell death.

Contact-inhibited cells, including the endothelium, have a reduced response to specific growth factors when they reach confluence ([@bib18]; [@bib57]). It is likely that the establishment of intercellular contacts transfers negative intracellular signals, which restrains the capacity of the cells to respond to proliferative signals. Cadherins have been implicated in this phenomenon. These adhesive transmembrane proteins are specifically located at intercellular adherens junctions and, once the cells get in contact, form zipper-like structures along intercellular contacts.

Endothelial cells express an endothelial-specific cadherin called vascular endothelial cadherin (VE-cadherin) ([@bib30]). This protein, like the other members of the family, is linked through its cytoplasmic tail to p120, β-catenin, and γ-catenin ([@bib24]). β- and γ-catenins, by binding to α-catenin, mediate the anchorage of VE-cadherin to the actin cytoskeleton. In addition, β-catenin, and in some conditions γ-catenin and p120, when released in the cytosol, can translocate to the nucleus and modulate cell transcription ([@bib24]).

β-Catenin is considered an oncogene and, in tumor cells, can induce transcription of genes important in cell cycle regulation ([@bib39]; [@bib11]; [@bib55]). Cadherins would therefore signal in an indirect way by linking β-catenin at the membrane and limiting in this way its translocation to the nucleus.

Epithelial cadherin (E-cadherin) was found to induce contact inhibition of cell growth ([@bib44]; [@bib35]). This effect requires binding of β-catenin to the cadherin cytoplasmic tail ([@bib25]; [@bib45]) and inhibition of its transcriptional activity.

Several studies indicate that adhesive proteins, such as integrins, can physically interact with growth factor receptors and synergistically modulate cell proliferation, migration, and survival ([@bib42]). Although less studied, cadherins or the cadherin--catenin complex can interact with growth factor receptors and some effectors of their signaling pathways ([@bib26]; [@bib38]; [@bib56]). In endothelial cells, VE-cadherin can associate with VEGFR-2 upon activation of the cells with VEGF. This interaction increases phosphatidylinositol 3 (PI3) kinase activation by the growth factor and improves cell survival ([@bib9]).

In this paper, we show that VE-cadherin exerts a more complex role on VEGF signaling through VEGFR-2. We found that VE-cadherin expression and clustering at intercellular junctions blocks the proliferative response of the cells to this growth factor, and inhibition of VEGFR-2 phosphorylation in tyrosine likely contributes to this effect. We propose that VE-cadherin acts, in part, by forming a complex with VEGFR-2 and bringing the receptor close to junctional phosphatases. VE-cadherin may, therefore, modulate VEGFR-2 signaling by increasing cell survival while inducing contact inhibition of cell growth.

Results
=======

VE-cadherin expression and clustering inhibit VEGF-induced endothelial proliferation
------------------------------------------------------------------------------------

Confluent endothelial cells respond poorly to growth factors as compared with sparse cells ([@bib15]; [@bib57]), suggesting that intercellular junctions may transfer growth inhibitory signals. To investigate whether VE-cadherin could play a role in this phenomenon, we compared syngenic endothelial cell lines differing for expression of VE-cadherin only. VE-cadherin--null and --positive cells (VEC null and VEC positive, respectively) retained the expression of all the endothelial-specific markers tested ([@bib32]). In addition, transfected VE-cadherin reached levels comparable to wild-type endothelium and was correctly organized at intercellular contacts ([@bib32]).

As shown in [Fig. 1](#fig1){ref-type="fig"} A, VEC-positive cells arrested their growth at confluence, whereas VEC-negative cells maintained a sustained growth rate reaching a two to threefold higher density than positive cells. Confluent VEC-positive cells behaved like wild-type endothelium ([@bib10]; [@bib57]), showing a markedly lower DNA synthesis upon VEGF stimulation than sparse cells ([Fig. 1](#fig1){ref-type="fig"} B). In contrast, VEC-null cells were highly responsive to VEGF both in sparse and confluent conditions. Thus, VE-cadherin substantially reduces the response of confluent, but not sparse, endothelium to VEGF.

![**Confluence and VE-cadherin expression inhibit endothelial proliferation induced by VEGF.** (A) Growth curve of endothelial cells expressing (VEC positive) or not expressing (VEC null) VE-cadherin. Cells (seeding 30,000/cm^2^) were cultured in complete culture medium. At the indicated time point, cells were detached and counted. The standard deviation in three independent experiments was between 5 and 10% of the mean values. (B) Confluent (100,000/cm^2^) and sparse (20,000/cm^2^) VEC-positive and VEC-null cells were stimulated with VEGF (80 ng/ml) for 24 h. BrdU (30 μM) was added during the last 4 h. A total of 300 nuclei in random fields for each treatment were scored. The mean values of three independent experiments ± SD are shown.](200209019f1){#fig1}

VE-cadherin expression inhibits VEGFR-2 phosphorylation
-------------------------------------------------------

VEGFR-2 plays a major role in the growth factor--induced endothelial cell proliferation ([@bib19]) and p44/42 MAP kinase activation ([@bib49], [@bib50]). In [Fig. 2](#fig2){ref-type="fig"} A, we show that the presence of VE-cadherin markedly reduced tyrosine phosphorylation of VEGFR-2 after VEGF activation of the cells. We then tested whether the correct clustering of VE-cadherin at junctions, and not only its expression, could affect receptor activation. As shown in [Fig. 2](#fig2){ref-type="fig"} B, sparse VEC-positive cells were able to respond to VEGF like null cells. Similarly, when freshly isolated human umbilical vein endothelial cells (HUVEC) were tested, VEGFR-2 phosphorylation was higher in sparse than in confluent cells ([Fig. 2](#fig2){ref-type="fig"} C).

![**VE-cadherin expression and clustering inhibit VEGFR-2 tyrosine phosphorylation.** (A) Confluent VEC-null and -positive endothelial cells were stimulated with VEGF (80 ng/ml) for the indicated time intervals. Cell extracts were immunoprecipitated with antibodies to VEGFR-2 (IP αVEGFR-2) and immunoblotted (IB) with antibodies to phosphotyrosine (αphosphoTyr) and VEGFR-2 (αVEGFR-2). A similar experimental procedure was used for B--D. In the representative experiment shown, tyrosine-phosphorylated VEGFR-2 normalized over total VEGFR-2 was 0.5-, five-, and twofold more in VEC-null than in VEC-positive cells at time 0, 5, and 30 min, respectively. In 15 independent experiments, the range of increase at 5 min was from two- to sevenfold. (B) Tyrosine phosphorylation of VEGFR-2 in response to VEGF (80 ng/ml for 5 min) in sparse VEC-null and -positive endothelial cells was comparable. (C) In HUVEC, phosphorylation of VEGFR-2 in response to VEGF (80 ng/ml for 5 min) was lower in confluent than in sparse cultures (range three- to fivefold lower in four experiments). (D) Addition of antibodies to VE-cadherin (anti-VEC, 100 μg/ml) for 1 h increased receptor phosphorylation by VEGF (80 ng/ml, for 5 min). In response to VEGF, the phosphotyrosine content in VEGFR-2 was higher (from three- to fourfold in three experiments) in cells pretreated with VE-cadherin antibody. The antibody to VEGFR-2 recognized two bands at a molecular mass of ∼200 kD. Only the higher molecular mass band, representing the mature form of the receptor, was phosphorylated in tyrosine, as also described by [@bib47]. In the following figures, we therefore show only the heavier band of the doublet, which represents the phosphorylable pool of VEGFR-2.](200209019f2){#fig2}

We have previously reported that the addition of VE-cadherin blocking antibodies to confluent endothelial cells abolished localization and clustering of the protein at intercellular contacts ([@bib14]). This effect was not accompanied by cell retraction or redistribution of other junctional proteins ([@bib13], [@bib14]). As shown in [Fig. 2](#fig2){ref-type="fig"} D, the addition of a blocking VE-cadherin monoclonal antibody to confluent HUVEC induces a three to fourfold increase in VEGFR-2 phosphorylation. Together, these data indicate that not only VE-cadherin expression, but also its correct organization and clustering at junctions, is required for an optimal inhibitory effect on VGFR-2 phosphorylation.

VEGFR-2 was similarly accessible to its ligand in confluent VEC-null and -positive cells. When a monoclonal antibody to the VEGF binding domain of the receptor (DC101) ([@bib59]) was added in vivo to both cell types, it could recognize a comparable amount of VEGFR-2 (Fig. S1, available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>).

VE-cadherin counteracts p44/42 MAP kinase phosphorylation induced by VEGF
-------------------------------------------------------------------------

Activation of MAP kinases is an important event in endothelial cell proliferation induced by growth factors ([@bib57]). As reported in [Fig. 3](#fig3){ref-type="fig"} A and Fig. S2 (available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>), in confluent but not in sparse cells, VE-cadherin expression reduced the peak and duration of MAP kinase phosphorylation induced by VEGF. Consistently, upon VEGF stimulation, sparse HUVEC presented higher MAP kinase activation than confluent cells ([Fig. 3](#fig3){ref-type="fig"} B).

![**VE-cadherin expression and clustering reduce the extent of p44/42 MAP kinase phosphorylation in response to VEGF.** (A) Confluent and sparse VEC-null and VEC-positive endothelial cells were stimulated with VEGF (80 ng/ml for 10 min), and phospho p44/42 MAP kinase and total MAP kinase were assayed by Western blot with specific antibodies. The columns represent the ratio between phosphorylated and total values as fold increase over the ratio calculated in sparse unstimulated VEC null. VEGF-stimulated phosphorylation of MAP kinases was reduced at confluence only in VEC-positive cells. The mean ± SD of three independent experiments is reported. In a total of 12 experiments, the increase of p44/42 MAP kinase phosphorylation in VEC-null cells ranged from three- to sixfold over VEC-positive cells. (B) In confluent HUVEC, phosphorylation of p44/42 MAP kinase in response to VEGF (80 ng/ml for 10 min) was reduced about threefold in comparison with sparse cells. Column values are as in A.](200209019f3){#fig3}

Treatment of VEC-null and -positive cells with PD98059 significantly reduced p44/42 MAP kinase activation and DNA synthesis after VEGF ([Fig. 4, A and B](#fig4){ref-type="fig"}). In addition, transfection of VEC-positive cells with a constitutive active MAP kinase kinase, but not with the wild-type construct or the empty vector, partially but significantly rescued cell proliferation.

![**Inhibition of p44/42 MAP kinase phosphorylation correlates with reduction of BrdU incorporation in VEC-null endothelial cells.** (A) Confluent VEC-null or -positive cells were treated with PD98059 (100 μM) for 20 min before challenge with VEGF (80 ng/ml for 10 min). VEC-positive cells were transfected with a constitutive active or wild-type MAP kinase kinase (MAPKK) construct or the empty vector. Nuclear incorporation of BrdU was evaluated after 24 h as in the legend to [Fig. 1](#fig1){ref-type="fig"}. PD98059 strongly inhibited proliferation of VEC-null cells in response to VEGF. Proliferation of VEC-positive cells was very low and was inhibited by the drug. Constitutively active MAPK kinase partially restored BrdU incorporation in response to VEGF in VEC-positive cells. (B) The concentration of PD98059 used in A was able to strongly inhibit phosphorylation of p44/42 MAP kinase after a 10-min stimulation with VEGF (80 ng/ml). Each column represents the fold increase of the ratio between phosphorylated and total values in VEGF-stimulated over the respective unstimulated condition. Data are means ± SD of three independent experiments. The vehicle is DMSO added at the same final concentration (0.1%) as in PD98059-treated cells.](200209019f4){#fig4}

Changing VEGF concentrations, both VEGFR-2 and p44/42 MAP kinase phosphorylation presented a dose-dependent response ([Fig. 5](#fig5){ref-type="fig"}). VEC-null cells always presented higher receptor phosphorylation and MAP kinase activation at all concentrations of VEGF used.

![**VE-cadherin expression down-regulates tyrosine phosphorylation of VEGFR-2 and phosphorylation of p44/42 MAP kinase over a range of VEGF concentrations.** Confluent VEC-null and -positive endothelial cells were challenged for 5 min with different concentrations of VEGF (0.8, 8, and 80 ng/ml). Phosphorylated and total VEGFR-2 (A) and p44/42 MAP kinase (B) were assayed as described in the legend to [Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. The fold increases of receptor and p44/42 MAP kinase phosphorylation in respect to unstimulated cells are reported on the right side of each panel. The SD was 5--15% of the means (three independent experiments).](200209019f5){#fig5}

VE-cadherin forms a complex with VEGFR-2
----------------------------------------

In previous work ([@bib9]), we found that VE-cadherin can be coimmunoprecipitated with VEGFR-2. We investigated whether this interaction is required for inhibition of VEGFR-2 phosphorylation. To this end, we analyzed VEC-null endothelial cells transfected with different mutants of VE-cadherin cytoplasmic tail. As described previously in detail ([@bib32]), mutant proteins are expressed at levels comparable to the wild type and are correctly clustered to cell--cell contacts. As reported in [Fig. 6](#fig6){ref-type="fig"} (A and C), when the region responsible for binding to β-catenin was truncated (from aa 703 to 784, Δ-βcat), VEGFR-2 could not associate with VE-cadherin. In contrast, when the region responsible for p120 association was deleted (from aa 621 to 702, Δ-p120), the receptor was still coimmunoprecipitated with VE-cadherin. Compared with null cells, expression of Δ-βcat did not change VEGFR-2 phosphorylation, whereas transfection of Δ-p120 reduced this parameter, although not as effectively as VE-cadherin wild type ([Fig. 6](#fig6){ref-type="fig"} A).

![**VEGFR-2 association and dephosphorylation requires the** β**-catenin binding domain of VE-cadherin.** VEC-null cells were transfected with VE-cadherin wild type or truncated mutants lacking β-catenin (Δ-βcat) or p120 (Δ-p120) binding domains. Intra, intracellular region; extra, extracellular region (C). (A) After stimulation with VEGF (80 ng/ml) for 5 and 30 min, cell extracts were immunoprecipitated (IP) with antibodies to VEGFR-2 (αVEGFR-2) and immunoblotted (IB) with antibodies to phosphotyrosine (αphosphoTyr), VEGFR-2 (αVEGFR-2), and VE-cadherin (αVEC). Wild-type (molecular mass, ∼120 kD) and Δ-p120 VE-cadherin (molecular mass, ∼100 kD) were coimmunoprecipitated with VEGFR-2 (A, lower panel). Receptor phosphorylation was significantly reduced in VEC-positive and Δ-p120, but not in Δ-βcat, in comparison with VEC-null cells. The quantification of receptor phosphorylation data from three experiments ± SD is shown in A on the right. The values represent the ratio between the phosphorylated and total amount of VEGFR-2 and are normalized to the ratio calculated in untreated VEC-positive cells. The peak of VEGFR-2 phosphorylation at 5 min is similar in VEC-null and Δ-βcat, but lower in Δ-p120. At longer stimulation (30 min), the level of phosphorylation of VEGFR-2 in Δ-p120 was comparable to VEC-positive cells. Incubation of VEC-positive cell extract with nonimmune (NI) rabbit immunoglobulin (matched with VEGFR-2 antibody used for IP) did not precipitate bands corresponding to either VEGFR-2 or VE-cadherin, last lane from the left (IP NI). (B) VE-cadherin mutants modulate endothelial growth induced by VEGF. VEC-null and Δ-βcat had comparable effects and were the most permissive mutations in terms of cell proliferation (\>160% increase over VEC-positive cells). Mutations that affected binding of p120 (Δ-p120) allowed cell proliferation, but to a lower extent (60% increase over stimulation of VEC-positive cells). Proliferation was measured as BrdU incorporation as described in the legend to [Fig. 1](#fig1){ref-type="fig"}. Mean ± SD of three independent experiments, each in duplicate, is shown.](200209019f6){#fig6}

The differences in receptor phosphorylation paralleled those in cell proliferation. [Fig. 6](#fig6){ref-type="fig"} B shows that Δ-βcat transfectants responded to VEGF as null cells, whereas Δ-p120 cells were partially inhibited. Coimmunoprecipitation experiments confirmed that Δ-βcat and Δ-p120 VE-cadherin mutants were unable to bind β-catenin or p120, respectively ([@bib32]).

β-Catenin is required for inhibition of VEGFR-2 phosphorylation
---------------------------------------------------------------

To investigate directly the role of β-catenin in VEGFR-2 phosphorylation, we tested β-catenin--null endothelial cells. These cells were isolated and cultured from animals carrying a null mutation of the *β-catenin* gene in endothelial cells specifically. Conditional gene inactivation was obtained by crossing mice carrying floxed *β-catenin* gene ([@bib6]) with transgenics expressing Cre under an endothelial-specific promoter (Tie-2 Cre) ([@bib27]; unpublished data; see Materials and methods for details).

As reported in [Fig. 7](#fig7){ref-type="fig"} (A and B), β-catenin was absent in these mutants whereas VE-cadherin expression was comparable. β-Catenin--null cells retained the endothelial cell markers tested (including VEGFR-2, Tie2, and CD34) and correctly organized junctions (as detected by the localization of VE-cadherin, ZO-1, occludin, PECAM, and JAM) ([Fig. 7](#fig7){ref-type="fig"} A; unpublished data). β-Catenin--null cells presented higher density at confluence and elongated morphology in comparison with the positive cells ([Fig. 7](#fig7){ref-type="fig"} A).

![**The absence of** β**-catenin enhances VEGF-induced phosphorylation of VEGFR-2 and cell proliferation.** Endothelial cells derived from β-catenin--null embryos (β-cat null) did not express β-catenin in comparison with cells obtained from β-catenin--positive (β-cat positive) littermate animals. (A) By immunofluorescence analysis, VE-cadherin was expressed at a comparable level and was concentrated at cell--cell contacts in both β-catenin--null and --positive cells. Cell junctions were negative for β-catenin in null cells. Bars: (phase contrast) 100 μm; (VE-cadherin and β-catenin) 20 μm. (B) Immunoprecipitation (IP) of cell extracts with VE-cadherin antibodies followed by Western blot (IB) with anti--VE-cadherin (αVE-cadherin) or β-catenin (αβ-catenin) antibodies showed absence of the last protein in the complex. (C) The absence of β-catenin enhanced the extent and duration of VEGFR-2 phosphorylation in response to VEGF (80 ng/ml). IP with anti--VEGFR-2 and Western blot with antiphosphotyrosine and anti--VEGFR-2 antibodies. (D) VE-cadherin could be coimmunoprecipitated with VEGFR-2 only in β-positive cells after VEGF (80 ng/ml for 5 min). IP with anti--VEGFR-2 and Western blot with anti--VEGFR-2 and anti--VE-cadherin antibodies. (E) Confluent β-cat--null endothelial cells incorporated BrdU 2--2.5-fold more than β-cat--positive cells in response to stimulation with VEGF (80 ng/ml for 24 h). Incorporation of BrdU was measured and calculated (mean of three independent experiments ± SD) as in [Fig. 1](#fig1){ref-type="fig"}. Two independent pairs of both β-positive and β-null endothelial cells obtained from littermate embryos of different mothers have been tested with comparable results.](200209019f7){#fig7}

In contrast to positive cells, when β-catenin--null cells were challenged with VEGF, VEGFR-2 could not be coimmunoprecipitated with VE-cadherin ([Fig. 7](#fig7){ref-type="fig"} D) and its phosphorylation was markedly increased ([Fig. 7](#fig7){ref-type="fig"} C). Consistently, endothelial cell proliferation in response to VEGF was increased in β-catenin--null cells ([Fig. 7](#fig7){ref-type="fig"} E). Comparable results were obtained using another β-catenin--null and another control cell line isolated from independent mice.

To test whether Cre expression may contribute to the observed functional behavior of β-catenin--null cells, we infected control cell lines with an adenoviral vector containing Cre cDNA as described previously ([@bib1]). Using two adeno Cre infections at 2 pfu/cell concentration at a 9-h interval, we did not observe significant changes in cell growth or response to VEGF (unpublished data). Overall, these data indicate that β-catenin expression and binding to VE-cadherin is required for inhibition of VEGFR-2 phosphorylation and down-regulation of cell proliferation.

Inhibition of VEGFR-2 phosphorylation is due to phosphatase activity: the role of DEP-1/CD148
---------------------------------------------------------------------------------------------

Treatment of VE-cadherin--positive cells with pervanadate (PV; from 100 μM vanadate and 200 μM H~2~O~2~), a general inhibitor of phosphatases ([@bib58]), restored the capacity of VEGF to induce VEGFR-2 phosphorylation at an even higher level than VE-cadherin--null cells (Fig. S3, available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>). These data link the inhibitory role of VE-cadherin to the activation or localization of phosphotyrosine phosphatase (PTP) activity.

Among different PTPs possibly implicated in this process, we studied the role of high cell density--enhanced PTP 1/CD148. This receptor-like PTP is of particular interest because it is up-regulated by cell density ([@bib36]), is expressed in endothelial cells of different origin, and, most importantly, codistributes with VE-cadherin at interendothelial junctions ([@bib48]).

To investigate the role of DEP-1 in VEGFR-2 phosphorylation, we transfected VE-cadherin--positive cells with either wild-type DEP-1 or a dominant-negative form of this PTP (DEP C/S). These constructs have been previously characterized in detail for expression and biological activity ([@bib28]; [@bib53]; [@bib2]). In addition, VE-cadherin--positive cells have been targeted with DEP-1--directed short interfering RNA (siRNA) or corresponding scramble oligonucleotides. None of the transfected cell lines presented changes in the morphology, retraction, or junctional distribution of VE-cadherin and β-catenin (Fig. S4, available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>).

As reported in [Fig. 8](#fig8){ref-type="fig"}, expression of VE-cadherin increased DEP-1 protein levels by 80--90% by Western blot analysis. Transfection of VE-cadherin--positive cells with wild-type and mutant DEP-1 constructs resulted in increased levels of the corresponding proteins by Western blot (∼50% in comparison with VEC positive). siRNA directed against DEP-1 reduced DEP-1 production by ∼40% in VE-cadherin--positive cells, whereas the scramble oligonucleotides did not have a significant effect.

![**Expression of tyrosine phosphatase DEP-1 in VEC-positive and -negative cells and effect of transfection of wild-type and DEP-1 C/S constructs and DEP-1 RNAi.** In VEC-positive endothelial cells (third lane), DEP-1 was 80--90% higher than in VEC null (fourth lane). In VEC-positive cells, transfection of wild-type (wt, first lane) or point-mutated (C/S, second lane) DEP-1 constructs resulted in increased expression of the protein (50--60% more than in control VEC positive). siRNA directed against DEP-1 (DEP siRNA) resulted in 35--40% inhibition of DEP expression (fifth lane). Scramble oligonucleotides (scr siRNA), used as control (100 nM as DEP siRNA oligonucleotide), were ineffective. Plus and minus indicate the presence or the absence of the protein indicated on the left. The columns report the mean of four experiments ± SD.](200209019f8){#fig8}

We then tested the effect of DEP-1 on VEGFR-2 phosphorylation. As shown in [Fig. 9](#fig9){ref-type="fig"}, DEP-1 C/S and siRNA partially restored VEGF-induced receptor phosphorylation in VE-cadherin--positive cells. Wild-type DEP-1 (DEPwt) and the scrambled oligonucleotides slightly, but not significantly, reduced VEGFR-2 activation. We obtained similar results when we measured the phosphorylation of Tyr 996 or 951 of the receptor (Fig. S5, available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>).

![**Down-regulation of DEP-1 increases VEGFR-2 phosphorylation.** Transfection of the dominant-negative DEP C/S mutant or DEP siRNA induced higher phosphorylation of VEGFR-2 upon VEGF (80 ng/ml for 5 min) than the respective controls, VEC positive, DEP wild type (DEP wt), and scramble siRNA (scr siRNA), respectively. Data were obtained by immunoprecipitation (IP) with anti--VEGFR-2 antibodies (αVEGFR-2) followed by Western blot (IB) with an antiphosphotyrosine antibody (αphosphoTyr). The graph was obtained by quantifying the gel bands and calculating the ratio of bands labeled with antiphosphotyrosine antibodies over total VEGFR-2. Each column represents the fold increase over unstimulated cells. Data are means ± SD of four experiments. Plus and minus indicate the presence or the absence of the protein indicated on the left.](200209019f9){#fig9}

Both DEP-1 C/S and siRNA had a partial, but significant, effect in restoring MAP kinase activation and BrdU uptake induced by VEGF in VEC-positive cells ([Fig. 10, A and B](#fig10){ref-type="fig"}). Wild-type DEP-1 (DEPwt) and the scrambled RNA did not have any effect.

![**Inhibition of DEP-1 enhances phosphorylation of p44/42 MAP kinase and BrdU nuclear incorporation in endothelial cells.** (A) Phosphorylation of p44/42 MAP kinase in response to VEGF (80 ng/ml for 10 min) is increased by 80--90% in VEC-positive cells expressing DEP C/S in comparison with control VEC positive. A similar increase is observed after DEP siRNA transfection of the cells. The graph represents the ratio between phosphorylated and total p44/42 MAP kinase as fold increase over untreated VEC-null cells. The values are means ± SD of four independent experiments. Plus and minus indicate the presence or the absence of the protein indicated on the left. (B) Nuclear incorporation of BrdU was stimulated by 80--100% in VEC-positive cells expressing C/S DEP or after DEP siRNA. BrdU incorporation was assayed as in [Fig. 1](#fig1){ref-type="fig"}. Data are means ± SD of four experiments.](200209019f10){#fig10}

Finally, we tested whether the effect of DEP-1 inhibition could increase phosphorylation of the receptor also in sparse cells, indicating a nonspecific, general effect of the phosphatase. As reported in Fig. S6 (available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>), the effect of DEP-1 C/S was apparent only in confluent cells, and no further increase in the phosphorylation of VEGFR-2 was detected in sparse cultures.

Discussion
==========

In this paper, we report that VE-cadherin expression is responsible, to a substantial extent, for the reduced response of confluent endothelial cells to VEGF-induced proliferation. VE-cadherin--positive or --negative cells respond equally well to the growth factor when they are sparse, but only VE-cadherin--positive cells become insensitive to VEGF at confluence. This indicates that the difference is not mediated by VE-cadherin expression, per se, but requires the establishment of intercellular contacts and cadherin clustering at junctions.

Other papers showed that expression of cadherins could strongly limit cell growth. E-cadherin and N-cadherin in different tumor cell lines induced contact inhibition of cell growth ([@bib44]; [@bib33]; [@bib25]; [@bib45]). This effect is mediated, at least in part, by the induction of cell cycle arrest at G1 phase likely due to dephosphorylation of retinoblastoma protein, elevation of the cyclin D1--dependent kinase inhibitor p27^kip1^, and late reduction of cyclin D1.

The growth inhibitory effects are believed to be mediated by the capacity of cadherins to link β-catenin at the membrane, limiting in this way its nuclear translocation. β-Catenin up-regulates transcription of cyclin D1 and c-myc ([@bib39]; [@bib24]; [@bib55]; [@bib11]), and inhibition of its activity would limit growth.

However, few observations do not perfectly fit in this picture. The addition of cadherin blocking antibodies restores growth in contact-inhibited cells ([@bib10]; [@bib44]) but does not change the cadherin--β-catenin complex ([@bib44]; [@bib12]). Similarly, in sparse or confluent cells, the VE-cadherin--β-catenin complex remains unchanged despite profound differences in growth ([@bib31]).

In this paper, we propose an additional mechanism through which cadherin expression may modulate growth. We found that VE-cadherin expression in confluent endothelial cells is accompanied by a strong reduction of VEGFR-2 phosphorylation. This effect was not due to down-regulation of VEGFR-2 because equal amounts of the protein were found in VE-cadherin--positive and --negative cells or in sparse and confluent cells. The accessibility of the receptor to its ligand, measured as binding of a mAb directed to the active site, was also unchanged.

VE-cadherin clustering at junctions was, however, necessary. The addition of anti--VE-cadherin antibodies, able to disrupt VE-cadherin clusters and induce a diffuse redistribution of the protein on the cell membrane, restores VEGFR-2 phosphorylation. In addition, VE-cadherin--positive, sparse cells behave like VE-cadherin--null cells.

These data are consistent with previous work by [@bib41], who showed that both removing divalent cations or adding VE-cadherin antibodies increased VEGFR-2 phosphorylation in endothelial cells. In addition, [@bib46] reported that in human breast epithelial cells, inhibition of E-cadherin clustering restored EGF receptor phosphorylation and cell response to this growth factor.

We published previously that VE-cadherin can form a complex with VEGFR-2 upon activation of the cells with VEGF, and this paralleled VEGFR-2 localization at intercellular junctions ([@bib9]; [@bib43]; [@bib60]). We therefore investigated whether the association of VE-cadherin with VEGFR-2 influences its phosphorylation. When the cytoplasmic tail of VE-cadherin is truncated in the β-catenin--binding domain, the complex cannot form and receptor phosphorylation is not inhibited. In contrast, when VE-cadherin is truncated in the p120 binding domain, it can still associate with VEGFR-2 like the wild type. Receptor phosphorylation in these cells was decreased at 5 min and lasted for a shorter time in comparison with VE-cadherin--null cells. This effect paralleled a reduction in VEGF-induced cell proliferation in Δ-p120 compared with VE-cadherin--null cells. The data discussed above suggested a role of cadherin-associated β-catenin in the inhibition of VEGFR-2 activation. This was further confirmed using β-catenin--null cells. These cells presented normal levels of VE-cadherin and all the other endothelial cell markers tested. In addition, VE-cadherin clustering at junctions as well as its association with γ-catenin/plakoglobin were retained. However, in these cells, VEGFR-2 association with VE-cadherin and its phosphorylation were not inhibited, and cells could still respond to the proliferative signal of VEGF.

Together, these data indicate that β-catenin is necessary for VEGFR-2 dephosphorylation and for down-regulation of cell growth. This observation is somehow in contrast with the general concept that β-catenin expression would favor, and not contrast, cell proliferation. Indeed, there may be cell-specific differences in the response to β-catenin among different cell types and among transformed and nontransformed cells as previously reported by [@bib40]. VE-cadherin--null, Δ-βcat, or β-catenin--null mutant cells behave similarly, suggesting that the effect on VEGFR-2 inactivation is related more to localization of β-catenin at the membrane than its nuclear translocation, which cannot occur in β-catenin--null cells. An attractive hypothesis is that the mechanism of action of the VE-cadherin--β-catenin--p120 complex comprises tethering VEGFR-2 to specific phosphatases, inhibiting in this way the degree and duration of its phosphorylation. This is supported by the observation that the general phosphatase inhibitor pervanadate blocks receptor inactivation by VE-cadherin.

Several phosphatases (PTPμ, PTP-K, SHP-1, SHP-2, PTP-LAR, and PTP-1B) ([@bib5]; [@bib4]; [@bib21]; [@bib29]; [@bib54]; [@bib52]) have been found to be directly or indirectly associated with the cadherin--catenin complex. Among these phosphatases, DEP-1/CD148 ([@bib36]) is of particular interest in endothelial cells. This type I membrane-associated phosphatase is expressed in many endothelial cell lines from different sources, is up-regulated by confluence, and is located at intercellular junctions ([@bib48]). Inactivation of its encoding gene induces a vascular phenotype characterized by enlarged, oversized vessels with abnormally high endothelial cell proliferation ([@bib51]). This suggests that the lack of DEP-1 activity leads to uncontrolled endothelial cell growth, and the data reported here may explain these observations. We show that DEP-1 contributes to VE-cadherin--induced inhibition of VEGFR-2 activation. When its activity or expression is inhibited, VEGFR-2 phosphorylation, activation of p44/42 MAP kinase, and cell proliferation are increased.

In previous papers, DEP-1 was found to codistribute with VE-cadherin at endothelial cell junctions; however, chelation of ions and disruption of VE-cadherin clusters did not change DEP-1 distribution ([@bib48]). This suggests that this phosphatase is contiguous but not directly associated with VE-cadherin. We propose that VE-cadherin binding to VEGFR-2 concentrates the receptor at junctions and makes it available to DEP-1 and possibly other junctional-associated phosphatases that would limit its activation. The partial rescue of a functional response to VEGF by dominant-negative DEP-1 and DEP-1--directed RNA interference (RNAi) (as well as constitutively activated MAPK kinase) could indicate that other mechanisms besides the effect on VEGFR-2 phosphorylation could be involved in contact inhibition of growth in response to this mitogen. These mechanisms could be operated by junctional β-catenin and act in parallel to the direct effect on the receptor.

It has been recently reported that DEP-1 can dephosphorylate the hepatocyte growth factor receptor Met at specific sites. This suggests that this phosphatase has a general role in regulating signaling from growth factor receptors ([@bib37]).

VEGFR-2 triggers different signaling pathways that mediate cell growth and survival. Activation of PLCγ ([@bib50]), and in some cases Ras ([@bib34]), would induce activation of a MAP kinase cascade and cell division. In contrast, PI3 kinase activation and Akt phosphorylation are mostly responsible, with some exception ([@bib16]), for promoting cell survival over apoptosis ([@bib22],[@bib23]).

Inhibition of VEGFR-2 activation by VE-cadherin would repress all its downstream signaling pathways. However, in previous work ([@bib9]), we observed that, instead, expression of VE-cadherin reinforced VEGFR-2 activation of PI3 kinase, accompanied by a marked decrease in endothelial cell sensitivity to apoptotic stimuli. This suggests that the effect of VE-cadherin is more complex and that this protein can direct VEGFR-2 signaling to specific pathways, inhibiting others. A possible explanation is that the phosphatase activity associated with the VE-cadherin--catenin complex may be specific for some VEGFR-2 tyrosines and not others. This would inhibit receptor interaction with some effectors without affecting other pathways. For instance, some authors reported that phosphorylation of tyrosine 1173 is crucial for PLCγ but not for PI3 kinase binding to VEGFR-2 ([@bib50]). In contrast, tyrosine 799 constitutes a binding site for the p85 element of PI3 kinase but not for PLCγ ([@bib16]). In this paper, we analyzed the behavior of tyrosine 951 and 996 because specific antibodies were available. These two tyrosines contribute to PLCγ and MAP kinase activation. We found that phosphorylation of both tyrosines was restrained by VE-cadherin expression and that this activity was restored by the DEP-1 dominant-negative mutant. A systematic analysis of the phosphorylation of all different tyrosines in VEGFR-2 in the presence or absence of VE-cadherin is underway.

In conclusion, in this paper we report that VE-cadherin expression and clustering may strongly modulate VEGFR-2 signaling. In confluent endothelial cells, VEGFR-2 would preferentially signal through PI3 kinase for survival, whereas in sparse cells, or in cells lacking VE-cadherin, it would mostly promote cell growth through MAP kinase activation. Thus, the same receptor, in the same cells and upon addition of the same agonist, would behave differently if associated or not with VE-cadherin. This introduces the idea that cadherins may contribute to receptor tyrosine kinase signaling by providing a docking platform for binding effectors and inhibitors, which may mediate the diversification of signaling pathways. The absence of VE-cadherin at junctions, as in VE-cadherin--null animals ([@bib9]) or in animals treated with blocking antibodies ([@bib12]), causes profound changes in vascular organization. The lack of modulation of VEGF signaling pathways may play an important role in these effects that lead to early lethality in the embryo and extensive vascular damage in the adult.

Materials and methods
=====================

Cell preparation and characterization
-------------------------------------

Endothelial cells were derived from murine embryonic stem cells with homozygous null mutation of the *VE-cadherin* gene (VEC null) as described in detail by [@bib3]. Wild-type and mutant forms of VE-cadherin were introduced in these cells using the retroviral vector PINCO, obtained through the courtesy of P.G. Pelicci (European Institute of Oncology, Milan, Italy) after the authorization of G.P. Nolan (Stanford University, Stanford, CA). Cell types that expressed the following proteins were generated: wild-type VE-cadherin (VEC positive), Δ-p120 (amino acid deletion 621--702, corresponding to the binding region of p120), and Δ-βcat (amino acid deletion 703--784, corresponding to the binding region of β-catenin). The details of the production and characterization of these cells were described by [@bib32].

The genes for human DEP/CD-148 wild type (DEP wt) and with cysteine 1239 mutated to serine (DEP C/S) ([@bib36]) were introduced in VEC-positive endothelial cells. The original constructs ([@bib48]) were cloned into PINCO retroviral vector, which also expressed GFP. Control cells were obtained by transfection with PINCO vector expressing GFP only. After infection, the GFP-positive cells were sorted. Expression of DEP, endogenous and neo-expressed, was assayed by Western blot with a mouse monoclonal antibody to ectodomain (clone D3F) and rabbit polyclonal antibody to cytoplasmic domain, which gave comparable results. Both antibodies recognized the human and mouse form of DEP.

The genes for hamster wild-type MAP kinase kinase (p45 MAPKK) and constitutively active MAP kinase kinase (with serine 218 and serine 222 both mutated to aspartic acid, D; [@bib7]) were also introduced in VEC-positive cells. The constructs, obtained through the courtesy of G. Pages (CNRS-UMR 6543, Nice, France), were cloned into PINCO vector, which also expressed the resistance to zeocin. Resistant cells were selected by culture in the presence of zeocin (300 μg/ml) for 20 d.

β-Catenin--positive and --null cells, wild type and homozygously null mutated in the *β-catenin* gene ([@bib6]), respectively, were isolated from 9.5-d postcoitum littermate embryos, as described in detail by [@bib3]. Expression of β-catenin protein was tested with the anti--β-catenin antibody by Transduction Laboratories (BD Biosciences), expression of VE-cadherin was tested with BV 13 ([@bib12]), and expression of VEGFR-2 was tested with sc504 by Santa Cruz Biotechnology, Inc. These cells have also been analyzed for the expression of β-catenin mRNA by PCR, expression of other endothelial markers (PECAM, Tie-2, and endoglin), as well as expression and distribution of junctional molecules (α-catenin, plakoglobin, ZO-1, and JAM).

For all the endothelial cells of murine origin, culture medium was DME (GIBCO BRL) with 10% fetal calf serum (HyClone), heparin (100 μg/ml, from porcine intestinal mucosa; Sigma-Aldrich), and endothelial cell growth supplement (5 μg/ml, made from calf brain) (complete culture medium). Culture medium for HUVEC was M199 (GIBCO BRL) with the same supplements.

RNAi
----

RNAi of DEP-1 expression was induced with siRNA directed against DEP. Positive 21-nucleotide siRNA (GGG.CCA.GGU.CCU.GUG.CGC.A.dT.dT. and U.GCG.CAC.GGA.CCA.GGU.CCC.dT.dT) targeted murine DEP-1 sequence 86 nucleotides downstream of the start codon. As a negative control, the Scramble II Duplex, siACE-RNAi, was used. Both positive and control oligonucleotides were from Dharmacon Research.

VEC-positive cells were seeded at a density of 20,000/cm^2^ the day before transfection, and they were ∼40% confluent at the time of transfection with 100 nM positive or scramble oligonucleotides in Oligofectamine (Invitrogen) and Optimem (GIBCO BRL), without serum or BSA. Before transfection, cells were washed once with Optimem. Transfection medium was maintained on cells for 4 h. Then it was removed and cells were cultured in complete medium. Transfection was repeated every 24 h for 2 d, and cells were used for the experiment after another 24 h. DEP expression was tested by Western blot as described above.

Proliferation assay
-------------------

Cells (50,000 cell/cm^2^) were cultured for 48 h in culture medium (1 ml) on fibronectin-coated (7 μg/ml; Sigma-Aldrich) glass coverslips set in a 24-well plate. Cell layers were washed once in MCDB 131 (GIBCO BRL) and cultured for another 24 h in MCDB 131 with 1% BSA, with a wash and change of medium after 24 h. Fresh MCDB 131 with 1% BSA was then added containing VEGF (80 ng/ml; PeproTech) when indicated. Cells were confluent during the stimulation (∼100,000 cell/cm^2^).

When subconfluent cultures were tested, cells at seeding were 5,000 cell/cm^2^, which reached a density of ∼20,000 cell/cm^2^ at the time of VEGF stimulation. At 20 h from the beginning of the stimulation, BrdU (30 μM) was added, and the incubation continued for another 4 h. Cells were then fixed with 3% paraformaldehyde and treated for 10 min with 2 N HCl. BrdU incorporation into nuclear structures was put in evidence with anti-BrdU antibodies (mouse monoclonal, Amersham Biosciences), followed by TRITC-conjugated antibody to mouse immunoglobulin (DakoCytomation) in the presence of Hoechst 33258 (0.1 μg/ml). Coverslips were mounted in Mowiol 4-88 (Calbiochem), and total and BrdU-positive cells were counted in random fields up to a number of 300 total nuclei/sample.

p44/42 MAP kinase phosphorylation assay
---------------------------------------

Cells (50,000 cell/cm^2^ and 5,000 cell/cm^2^, to obtain confluent and subconfluent cultures at the time of stimulation, see previous section) were cultured on gelatin-coated (0.1%; Difco) plastic tissue culture vessels for 48 h in culture medium and for another 48 h in 1% BSA-MCDB 131, as described in detail in the Proliferation assay section. 2 h before stimulation, cells were washed once with MCDB 131 and incubated in MCDB 131 with 1% BSA. Medium was replaced with fresh 1% BSA-MCDB 131 just before stimulation with VEGF (80 ng/ml). Control cells had exactly the same treatment without VEGF. At different times after VEGF, as indicated in the specific sections, cells were washed twice with PBS and extracted in boiling Laemli sample buffer containing DTT (50 mM). Cells were scraped and further boiled for 10 min. A parallel sample for each cell type was extracted without DTT for assay of protein content with BCA reagent by Pierce Chemical Co. A total of 15 μg protein was loaded for each lane of a 12% polyacrylamide gel, separated by SDS electrophoresis, and transferred to nitrocellulose (Schleicher & Schuell). To evaluate the phosphorylation of p44/42 MAP kinase, the antibodies (rabbit polyclonal) from Cell Signaling, which specifically recognize the Thr202 and the Tyr204 of p44/42 MAP kinase when phosphorylated, were used. The total content of MAP kinase was assayed in a parallel run using anti--total MAP kinase (rabbit polyclonal; Cell Signaling). Western blots were developed with HRP-conjugated anti--rabbit immunoglobulin (Cell Signaling) followed by ECL (Pierce Chemical Co.). The signals on film (Hyperfilm ECL; Amersham Biosciences) were scanned and quantified using the NIH Image 1.62 program for Macintosh (developed at the National Institutes of Health and freely available at <http://rsb.info.nih.gov/nih-image/>). The gel images presented have been prepared using Adobe Photoshop 7.0^®^ and combined with Excel graphics in Canvas 8. All the programs were versions for Macintosh.

VEGFR-2 phosphorylation assay
-----------------------------

Cells were cultured exactly as described in the previous section for assaying p44/42 MAP kinase phosphorylation. To measure the level of total phosphotyrosine in VEGFR-2, cells were extracted in lysis buffer, as described in detail by [@bib60], and immunoprecipitated with antibodies to VEGFR-2 (sc504, mapping at the carboxy terminus 1158--1345; Santa Cruz Biotechnology, Inc.). Protein content was measured (BCA reagent; Pierce Chemical Co.), and ∼1 mg cell extract for each sample was immunoprecipitated with 20 μg anti--VEGFR-2 conjugated to 20 μl protein A agarose (Amersham Biosciences). Two thirds of the Laemmli sample buffer in which the immunoprecipitates were finally recovered ([@bib60]) was run in SDS-PAGE (7% polyacrylamide) for blot with antiphosphotyrosine (PY20; Transduction Laboratories). The remaining one third was run in parallel and blotted with antibodies to VEGFR-2, to normalize the level of phosphorylation to the level of total VEGFR-2 immunoprecipitated. Quantification of the specific bands was as described in the previous section.

Online supplemental material
----------------------------

The supplemental material (Figs. S1--S6) is available at <http://www.jcb.org/cgi/content/full/jcb.200209019/DC1>. A concise description of the data presented in each supplemental figure is introduced upon citation in the text. Details on the experimental procedure and further comments on the data reported can be found in the online legends.
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